https://doi.org/10.4081/reumatismo.2022.1440
COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis
Submitted: 15 June 2021
Accepted: 12 March 2022
Published: 3 May 2022
Accepted: 12 March 2022
Abstract Views: 1988
PDF: 508
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Borges et al. have recently reported the first case of a dermatomyositis onset in close association with established coronavirus disease 2019 (COVID-19). Similarly, we report a patient who, on the contrary, had COVID-19 following early established dermatomyositis. We report prospectively the outcome of her disease.
Lundberg I, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017; 76: 2271-82.
DOI: https://doi.org/10.1002/art.40320
Borges NH, Godoy TM, Kahlo BS. Insorgenza di dermatomiosite in stretta associazione con COVID-19 - un primo caso riportato. Rheumatology (Oxford) 2021.[Epub ahead of print].
Ahmed S, Zimba O, Gasparyan AY. COVID-19 e il corso clinico delle manifestazioni reumatiche. Clin Rheumatol. 2021: 1-9.
Raghavan S, Gonakoti S, Asemota IR, Mba B. Un caso di flare di lupus eritematoso sistemico innescato da una grave malattia da coronavirus 2019. J Clin Rheumatol. 2020; 26: 234-36.
DOI: https://doi.org/10.1097/RHU.0000000000001531
Lokineni S, Mortezavi M. Miosite necrotizzante a insorgenza ritardata dopo infezione da COVID-19. Eur J Case Rep Int Med. 2021; 8: 002461.
De Souza JM, Hoff LS, Shinjo SK. Terapie a impulsi di immunoglobulina umana per via endovenosa e/o metilprednisolone come possibile strategia treat-to-target nelle miopatie necrotizzanti immunomediate. Rheumatol Int. 2019; 39: 1201-12.
DOI: https://doi.org/10.1007/s00296-019-04254-3
De Souza, Miossi R, Shinjo SK. Miopatia necrotizzante associata ad anticorpo anti-signal recognition particle (anti-SRP). Clin Exp Rheumatol. 2017; 35: 766-71.
How to Cite
Faria, M., & Shinjo, S. (2022). COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis. Reumatismo, 74(1). https://doi.org/10.4081/reumatismo.2022.1440
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- J. Mencarini, M. Spinicci, F. Bartalesi, Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter? , Reumatismo: Vol. 68 No. 3 (2016)
- F.M. Perrotta, E. Lubrano, New approved drugs for psoriatic arthritis , Reumatismo: Vol. 68 No. 2 (2016)
- F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro, Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs , Reumatismo: Vol. 66 No. 3 (2014)
- C.-N. Lo, G. Xia, B.P. Leung, The effect of nerve mobilization exercise in patients with rheumatoid arthritis: a pilot study , Reumatismo: Vol. 69 No. 3 (2017)
- A. Ghirardello, S. Zampieri, L. Iaccarino, E. Tarricone, M. Tonello, R. Bendo, R. Rondinone, F. Cozzi, A. Doria, Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients , Reumatismo: Vol. 57 No. 1 (2005)
- L. De Falco, A. Fioravanti, M. Galeazzi, S. Tenti, Bradykinin and its role in osteoarthritis , Reumatismo: Vol. 65 No. 3 (2013)
- F.I. Gorial, N.I. Awadh, A. Al-Shakarchi, G. Al-Gburi, Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report , Reumatismo: Early Access
- F. Atzeni, L. Boccassini, M. Di Franco, A. Alciati, A. Marsico, M. Cazzola, G. Cassisi, P. Sarzi-Puttini, Chronic widespread pain in spondyloarthritis , Reumatismo: Vol. 66 No. 1 (2014)
- C. Ferrone, R. Andracco, M.A. Cimmino, Calcium pyrophosphate deposition disease: clinical manifestations , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- D. Fornasari, S. Coaccioli, Pharmacology of pain , Reumatismo: Vol. 66 No. 1 (2014)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
